Active not recruitingOBSERVATIONAL

Consistency of Response With Rimegepant in Acute Treatment of Migraine

This UK study is looking at how consistently a medicine called rimegepant helps people who get migraine attacks. If you are already taking rimegepant to treat your migraines, you might be able to join. We want to understand how well the medicine works for you every time you take it. Participants will answer a short daily questionnaire online for 12 weeks about their migraine attacks and how rimegepant helps. This helps researchers see how the medicine works in real life for many different attacks. The results will help doctors and patients understand more about using rimegepant for migraines.

At a glance

Status

Active not recruiting

Sponsor

Pfizer

Enrolment target

250

Start

15 Nov 2025

Estimated completion

31 Jul 2026

Migraine

What is this study about?

This study is about understanding how a medicine called rimegepant works for people who get migraines in the UK. Rimegepant is used to treat migraine attacks when they happen. We want to know how well and consistently it works for people in their everyday lives. Is it always helpful? Does it work similarly each time you take it for an attack? By gathering information directly from people using the medicine, we can get a real-world picture.

This isn't a test of a new medicine; it's about learning from people already using rimegepant as part of their regular migraine treatment. The aim is to collect information over several months to understand treatment effectiveness during different migraine attacks. This kind of study helps make sure the information we get is as close to real life as possible, which is really valuable for doctors and other patients.

Your involvement would help researchers understand if rimegepant works consistently for different people, whether they have occasional (episodic) migraines or more frequent (chronic) migraines. This information helps healthcare professionals give the best advice and support to people living with migraines.

Key takeaways

Study about how well migraine medicine rimegepant works for UK patients already using it.
Share your daily experiences online for 12 weeks.
No new medicines or clinic visits; continue your usual care.
Helps doctors understand how rimegepant works in real life.
Your privacy is protected, and you can leave anytime.

Who may be eligible?

To join this study, you must live in the UK and be at least 18 years old. A doctor must have diagnosed you with migraine, and you must currently have a prescription for rimegepant that you use to treat your migraine attacks when they happen. You also need to have experienced at least four migraine attacks per month before the study started.

If you're taking another medicine to prevent migraines (a 'preventive treatment'), that treatment needs to be stable, meaning you've found the right dose, and it hasn't changed recently. For example, if you take a monthly preventive, your last dose should have been within the last three weeks. If it was longer ago, you might be able to join after your next dose.

You cannot join if you're using rimegepant as a preventive medicine (to stop migraines from happening regularly), or if you have certain other headache types like cluster headache or specific severe neurological or mental health conditions. Also, you can't join if you're taking medicines that might strongly interact with rimegepant, or if you're already part of another migraine-related clinical trial.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 or older and live in the UK?
Has a doctor told you that you have migraines?
Are you currently prescribed rimegepant to treat your migraine attacks?
Do you usually have at least 4 migraine attacks each month?
Do you not have certain other serious health conditions like cluster headache, severe depression, or specific neurological disorders?

Answer every question to see your result.

What does participation involve?

If you join, you'll be asked to complete some initial questions about yourself and your migraine history online within three days of registering. Then, for 12 weeks, you'll receive a message on your phone each day with a link to a secure website. You'll need to answer a short daily questionnaire online about your migraine symptoms and how rimegepant works for you. This helps us get details about each migraine attack as it happens. There are no clinic visits, new medications, or tests involved. You will continue to use your prescribed rimegepant as normal. The total time you'll be actively involved in answering questions is about 12 weeks.

Potential risks and benefits

Taking part in this study does not involve any medical treatments or changes to your current care, so there are very few direct risks. The main commitment is your time to complete the daily questions. A potential benefit is that by sharing your experiences, you'll be helping researchers gather important information about how rimegepant works in real-life situations. This can benefit other people with migraines in the future. Remember, you can choose to leave the study at any time, for any reason, without it affecting your medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Pfizer
Verified postcode
London, United Kingdom

Common questions

What is rimegepant?

Rimegepant is a medicine prescribed by doctors to treat migraine attacks when they happen, to help relieve your symptoms.

Will I get free medicine if I join?

No, this study is for people who are already prescribed rimegepant and are using it. You'll continue to get your medicine from your usual doctor.

Do I have to go to a clinic?

No, this study is all done online from home. You'll answer questions using a secure website.

How long will I be in the study?

You'll answer daily questions for about 12 weeks (roughly 3 months).

Is my personal information safe?

Yes, your privacy and personal data are protected. You'll use a unique ID, and all information collected will be handled confidentially.